Low molecular weight heparins in the cardiac catheterization laboratory

J Thromb Thrombolysis. 1999 Jun;7(3):319-23. doi: 10.1023/a:1008943529597.
No abstract available

Publication types

  • Review

MeSH terms

  • Abciximab
  • Angina, Unstable / diagnosis
  • Angina, Unstable / drug therapy
  • Angioplasty, Balloon, Coronary / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Anticoagulants / pharmacology
  • Anticoagulants / therapeutic use*
  • Aspirin / therapeutic use
  • Cardiac Catheterization / adverse effects*
  • Clinical Trials as Topic
  • Clopidogrel
  • Drug Therapy, Combination
  • Enoxaparin / therapeutic use
  • Fibrinolytic Agents / pharmacology
  • Fibrinolytic Agents / therapeutic use*
  • Heparin / pharmacology
  • Heparin / therapeutic use
  • Heparin, Low-Molecular-Weight / pharmacology
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use
  • Platelet Aggregation Inhibitors / therapeutic use
  • Stents
  • Thrombosis / prevention & control*
  • Ticlopidine / analogs & derivatives
  • Ticlopidine / therapeutic use
  • Tunica Intima / drug effects*
  • Tunica Intima / injuries

Substances

  • Antibodies, Monoclonal
  • Anticoagulants
  • Enoxaparin
  • Fibrinolytic Agents
  • Heparin, Low-Molecular-Weight
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Heparin
  • Clopidogrel
  • Ticlopidine
  • Aspirin
  • Abciximab